AACR 2024 | The future role of lifileucel in melanoma

Sebastian Klobuch, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, comments on the emerging role of lifileucel in melanoma, following its recent approval by the FDA. Lifileucel, a tumor-infiltrating lymphocyte (TIL), has shown to be a promising option in patients who progress on immune checkpoint inhibitors, and the Phase III TILVANCE-301 trial (NCT05727904) will assess lifileucel with pembrolizumab versus pembrolizumab alone in the first line setting. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.